<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993446</url>
  </required_header>
  <id_info>
    <org_study_id>DRM02-ROS02</org_study_id>
    <nct_id>NCT01993446</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of DRM02 in Subjects With Rosacea</brief_title>
  <official_title>A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DRM02 is safe and effective in the&#xD;
      treatment of rosacea when applied twice daily for 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, vehicle controlled, study enrolling 30 subjects with&#xD;
      rosacea and designed to assess the safety, tolerability, and preliminary efficacy of DRM02.&#xD;
&#xD;
      Safety will be assessed during the study, through adverse events, local skin responses,&#xD;
      urinalysis, serum chemistry and hematology laboratory testing, physical examination and vital&#xD;
      signs.&#xD;
&#xD;
      Preliminary efficacy will be assessed through inflammatory lesion counts, the Investigator's&#xD;
      Global Evaluation (IGE) and the Rosacea Signs and Symptoms (RSS) scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammatory lesion count</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Evaluation (IGE)</measure>
    <time_frame>From baseline to weeks 0, 1, 2, 3, 4 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGE dichotomized into &quot;success&quot; and &quot;failure&quot;</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in inflammatory lesions</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rosacea Signs and Symptoms (RSS)</measure>
    <time_frame>From baseline to weeks 0, 1, 2, 3, 4 and 6</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>DRM02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DRM02 Topical Gel, 0.25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DRM02 Topical Gel, Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRM02</intervention_name>
    <arm_group_label>DRM02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 to 70 years of age.&#xD;
&#xD;
          -  Clinical diagnosis of rosacea with a score of 2 or 3 on the Investigator's Global&#xD;
             Evaluation (IGE) of Rosacea scale and at least 15 and not more than 40 papules.&#xD;
&#xD;
          -  Subjects willing to minimize external factors that might trigger rosacea flare-ups.&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating females.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe self-reported facial sensitivity.&#xD;
&#xD;
          -  Severe sun sensitivity.&#xD;
&#xD;
          -  Ocular-only, phymatous rosacea or steroid rosacea.&#xD;
&#xD;
          -  Use of topical rosacea treatments in the 4 weeks prior to baseline.&#xD;
&#xD;
          -  Use of systemic corticosteroids within the 4 weeks prior to baseline.&#xD;
&#xD;
          -  Use of systemic antibiotics in the 4 weeks prior to baseline.&#xD;
&#xD;
          -  Use of systemic retinoids for in the 6 months prior to baseline.&#xD;
&#xD;
          -  Use of topical retinoids in the 3 months prior to baseline.&#xD;
&#xD;
          -  Use of light- or laser-based rosacea treatments in the past 2 months prior to&#xD;
             baseline.&#xD;
&#xD;
          -  Cosmetic procedures within the 2 months prior to baseline.&#xD;
&#xD;
          -  Use of topical anti-aging medications in the 2 weeks prior to baseline.&#xD;
&#xD;
          -  Subjects who have poor skin condition within 5 cm of the treatment area.&#xD;
&#xD;
          -  Subjects who are current drug or alcohol abusers; have a history of immunodeficiency&#xD;
             or are a poor medical risk because of other systemic diseases or active uncontrolled&#xD;
             infections.&#xD;
&#xD;
          -  Subjects with an unstable medical condition or a medical condition not adequately&#xD;
             controlled with standard medical therapy.&#xD;
&#xD;
          -  Subjects who are actively participating in an experimental therapy study or who have&#xD;
             received experimental therapy within 30 days.&#xD;
&#xD;
          -  Subjects who have a clinically significant laboratory value at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth Zib</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Windsor Clinical Research, Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique MÃ©dicale Dr Isabelle Delorme</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <zip>J2B5L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research, Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

